Are incentive-based formularies inversely associated with drug utilization in managed care?

Annals of Pharmacotherapy

Volumn 39, Issue 2, 2005, Pages 339-345

  Gleason, Patrick P ^a,b   Gunderson, Brent W ^a   Gericke, Kristin R ^c,d  

^a Prime Therapeutics LLC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Clinical Pharmacy Management   (United States)

Author keywords

Cost sharing; Drug utilization; Formularies; Managed care

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

COST BENEFIT ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG UTILIZATION; FOLLOW UP; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MANAGED CARE; PRIORITY JOURNAL; REVIEW; SALARY; WORKMAN COMPENSATION;

FEES, PHARMACEUTICAL; HUMANS; MANAGED CARE PROGRAMS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT, INCENTIVE;

EID: 12844277255     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E380     Document Type: Review

References (24)

1. Center for Medicaid and Medicare Services (CMS). Table 11. Prescription drug expenditures; aggregate and per capita amounts, percent distribution and average annual percent change by source of funds: selected calendar years 1990-2013. www.cms.hhs.gov/statistics/nhe/projections-2003/t11.asp (accessed 2004 Jun 16).
2. Mahan D. Sticker shock: rising prescription prices for seniors. Washington, DC: Families USA, June 2004. www.familiesusa.org/site/DocServer/ Sticker_Shock.pdf?docID=3541 (accessed 2004 Jun 16).
3. Malkin JD, Goldman DP, Joyce GF. The changing face of pharmacy benefit design. Health Aff (Millwood) 2004;23:194-9.
4. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther 2003;25:250-72.
5. Center for Medicare and Medicaid Services. The facts about upcoming new benefits in Medicare. Medicare Modernization Act of 2003. February 17, 2004. Publication no. CMS-11054. www.cms.hhs.gov/medicarereform (accessed 2005 Jan 3).
6. Robinson JC. Reinvention of health insurance in the consumer era. JAMA2004;291:1880-6.
7. Kaiser Family Foundation. Prescription drug trends. Trends and indicators in the changing health care marketplace, 2004 update. Publication no. 7031. www.kff.org/insurance/7031/index.cfm (accessed 2004 Jul 8).
8. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA 2002;288:1733-9.
9. Hensley S. Employers use co-payments to keep drug costs in line. Wall Street Journal May 10, 2004. http://webreprints.djreprints.com/ 1077151057910.html (accessed 2005 Jan 3).
10. Hensley S. From 'one size fits all' to tailored co-payments. Wall Street Journal June 16, 2004.
11. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9.
12. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001;39:1293-304.
13. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther 2003;25:3147-61.
14. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003;349:2224-32.
15. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA 2004;291:2344-50.
16. Motheral BR, Henderson R. The effect of copay increase on pharmaceutical utilization, expenditures, and treatment continuation. Am J Managed Care 1999;5:1383-94.
17. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on prescription purchasing behavior of individuals with chronic disease. J Managed Care Pharm 2003;2:123-33.
18. Harris BL, Stergachis A, Ried DL. The effect of co-payments on utilization and costs of pharmaceuticals in a health maintenance organization. Med Care 1990;23:907-17.
19. Kamal-Bahl S, Briesacher B. How do incentive based formularies influence drug selection and spending for hypertension? Health Aff (Millwood) 2004;23:227-36.
20. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.
21. Heisler M, Langa KM, Eby EL, Fendrick AM, Kabeto MU, Piette JD. The health effects of restricting prescription medication use due to cost. Med Care 2004;42:626-34.
22. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med 2004;164:1679-84.
23. Meissner BL, Moore WM, Shinogle JA, Reeder CE, Little JM. Effects of an increase in prescription copayment on utilization of low-sedating anti-histamine and nasal steroids. J Managed Care Pharm 2004;10:226-33.
24. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003;74:388-400.